The short version of preclinical model fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-09 and is reviewed periodically as new material appears.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentadecapeptide | Composed of fifteen amino acid residues |
| Amino acid sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | Single-letter form GEPPPGKPADDAGLV |
| Original source | Fragment of a protein in human gastric juice | First characterized in the 1990s |
| Number in name | 157 | Refers to the fragment's position in the source protein |
| Human trial evidence | Limited | Preclinical rodent data predominate |
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
== Further reading == Payne M.G., Hurst G.S. (1985) Theory of Resonance Ionization Spectroscopy. In: Martellucci S., Chester A.N. (eds) Analytical Laser Spectroscopy. NATO ASI Series (Series B: Physics), vol 119. Springer, Boston, MA. Parks J.E., Young J.P. (2000) Resonance Ionization Spectroscopy 2000: Laser Ionization and Applications Incorporating RIS; 10th International Symposium, Knoxville, Tennessee (AIP Conference Proceedings).
==== Reproducibility ==== In 1989, after Fleischmann and Pons had made their claims, many research groups tried to reproduce the Fleischmann-Pons experiment, without success. A few other research groups, however, reported successful reproductions of cold fusion during this time. In July 1989, an Indian group from the Bhabha Atomic Research Centre (P. K. Iyengar and M. Srinivasan) and in October 1989, John Bockris' group from Texas A&M University reported on the creation of tritium. In December 1990, professor Richard Oriani of the University of Minnesota reported excess heat. Groups that did report successes found that some of their cells were producing the effect, while other cells that were built exactly the same and used the same materials were not. Researchers who continued to work on the topic have claimed over the years that many successful replications had been made, but still had problems getting reliable replications. Reproducibility is one of the main principles of the scientific method, and its lack led most physicists to believe that the few positive reports could be attributed to experimental error. The DOE 2004 report said among its conclusions and recommendations:
== Production == Aerated chocolate containing large bubbles is produced via two methods. In the first, melted chocolate is put under a vacuum, where it foams up. As the chocolate cools, and the fats within the chocolate set, the foam structure remains. Sometimes gases such as carbon dioxide are introduced into the mixture before it is placed under the vacuum. Although the method easily permits inclusions such as nougat or nuts, the production is labor-intensive and difficult to keep hygienic. As a result, the second method is more frequently used: working gases into liquid, tempered chocolate under high pressure. Carbon dioxide is mainly used, although others include nitrous oxide. Air is avoided, as oxygen causes chocolate to become rancid. Any gases that do not dissolve are dispersed as bubbles through the chocolate using a beater. As the chocolate is released from the high pressure conditions, the bubbles expand, foaming the product; through this, the amount of pressure directly impacts bubble size. The setting chocolate is deposited in a moulded shell, after which the set interior is capped with liquid tempered chocolate. Factors that affect bubble size include qualities of chocolate, such as viscosity and the rate of setting. The ingredients used, such as emulsifiers and milk fats also impact bubble size; other factors include type of gas and how much pressure is applied. Micro-aerated chocolate is created using the method of beating gases in under high pressure.
Sources: en.wikipedia.org
=== Interchangeability of centipede species in clinical practices === Comparative studies on S. mutilans and S. mojiangica, a common substitute for the former, has found that in pharmacodynamics and toxicology, the two centipede species have similar effects, and is theoretically proved that S. mutilans can be replaced by S. mojiangica. The same study found that two species showed similar results in various fields, including effects on animal haemoglobin and weight, chromosomal aberration tests, anticonvulsive tests, effects on in vitro fungal and bacterial growth, and acute toxicity tests. The study also suggested both centipede species can be used in relatively large doses, as they were both low in acute and genetic toxicities. Although the two centipede species were shown to be interchangeable in clinical practices, their interchangeability in clinical application was again questioned by some researchers, as more recent studies suggested that centipede proteins have a major role in their clinical effects. Through proteomics, researchers had found that the venoms of S. monjiangica and S. mutilans are different in the number of overlapping sequences and precursors for proteins and peptides. In addition, unique precursors were also found in both species for proteins and peptide levels. As the species differ in protein and peptide level, researchers of this study concluded that the interchangeability of centipede species requires further evaluation.
MuscleTech is a brand of dietary supplements, marketed by Iovate Health Sciences Inc., which includes Hydroxycut. It was owned by Canadian company Kerr Holdings which was acquired by Xiwang Foodstuffs Company, a Chinese company, for $584 million in 2016.
The evidence suggests "consumers pay lower electricity net-of-tax prices in countries where there are still incumbents owned by national governments." With the sharp rise in fossil fuel prices that came from the 2022 Russian invasion of Ukraine and the fossil fuel cartel OPEC deciding to restrict supply, the EU Commission proposed a windfall fossil fuel tax. There are not yet common standards on energy enterprise governance, although a number of member states ensure that workers and energy bill payers have the right to vote for directors.
DM is paraneoplastic in up to 40% of cases, most commonly in association with underlying malignancy in patients with anti–TIF1γ autoantibodies. A majority of patients with paraneoplastic dermatomyositis harbor somatic mutations or other genetic alterations in tumor genes encoding the target autoantigens of their corresponding autoantibodies, suggesting that, in this context, autoantibody production arises secondary to an anti-tumor immune response that fails to achieve effective tumor control.The most commonly associated cancers are ovarian cancer, breast cancer, and lung cancer overall, but the most frequent associations can vary depending on patient race or ethnicity. Inherited genetic factors confer a predisposition to developing these diseases, and HLA subtypes HLA-DR3, HLA-DR52, and HLA-DR6 seem to create a disposition to DM.
Sources: en.wikipedia.org
In Sri Lanka, a Member of Parliament refers to a member of the Parliament of Sri Lanka (since 1978), the National State Assembly (1972–78) and the House of Representatives of Ceylon (1947–72), the lower house of the Parliament of Ceylon. Members are elected in a general elections or appointed from the national lists allocated to parties (and independent groups) in proportion to their share of the national vote at a general election. A candidate to become an MP must be a Sri Lankan citizen and can be a holder of dual-citizenship in any other country, be at least 18 years of age, and not be a public official or officeholder.
Humps which mostly contain fat can shrink or disappear depending on conditions. When camels are born, the humps are small and may appear deflated, but will grow as the calf begins to eat solid food. Adult camels that suffer extreme stress, such as heavy parasite loads, may lose their humps due to depletion of fat reserves. Captive plains bison may arch their backs (or "hump up") as a stress response, especially if in close confinement, which can create the illusion that their actual hump is much lower at the shoulders. Humps can take different forms, even between closely related species. The dromedary camel has only one hump, while the bactrian camel has two. This may be due to differences in fat metabolism rates, as the two-humped bactrian evolved lipid metabolism more rapidly. Yaks have humps comparable to the breastbone of a bird, while zebus have lump-like humps; when the two are crossbred, the yak's hump gene is dominant over the zebu's. In some cattle breeds, like the Drakensberger and Nguni, the hump is sexually dimorphic, with only bulls having one. In other breeds, like the Boran, both sexes have a hump, but it is larger in the male.
== Medical uses == Zalcitabine was the third antiretroviral to be approved by the Food and Drug Administration (FDA) for the treatment of HIV/AIDS. It was approved on June 19, 1992, as a monotherapy and again in 1996 for use in combination with zidovudine (AZT). Using combinations of NRTIs was in practice prior to the second FDA approval and the triple drug combinations with dual NRTIs and a protease inhibitor (PI) were not far off by this time. In 1992 dideoxycytidine was listed as a specialty drug. The sale and distribution of zalcitabine has been discontinued since December 31, 2006.
Sources: en.wikipedia.org
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.
It is neither a naturally circulating hormone nor an approved medicine in most countries. It is a synthetic peptide fragment used chiefly as a laboratory research material. Its regulatory status varies by jurisdiction, and it is not authorized as a therapeutic product in the United States or the European Union.
Published human evidence is very limited. Most findings come from rodent studies conducted by a small number of groups. As a result, statements about its effects in humans are generally described as uncertain rather than established.
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.